Latest Ratios: P/E Ratio -4.9x · EV/EBITDA N/A · ROE 15.0%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $209M | $229M | $35M | $38M | $26M | $214M | — | — |
| Enterprise Value | $204M | $225M | $31M | $-12674527 | $17M | $189M | — | — |
| P/E Ratio → | -4.94 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 26.54 | 16.96 | 1.07 | 3.51 | — | — |
| P/B Ratio | 1.58 | 1.51 | 1.35 | 0.66 | 0.83 | 5.54 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | 107.47 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 23.35 | -5.66 | 0.69 | 3.10 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | 16.64 | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | -262.4% | -67.3% | 86.2% | 97.3% | 100.0% | 100.0% |
| Operating Margin | — | — | -3244.9% | -1700.5% | -121.0% | -22.0% | 37.2% | -252.0% |
| Net Profit Margin | — | — | -2579.0% | -1884.5% | -78.4% | -28.2% | 36.4% | -261.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | 15.0% | 15.0% | -81.9% | -95.5% | -53.8% | -44.2% | 109.6% | — |
| ROA | 12.2% | 12.2% | -53.2% | -62.6% | -28.4% | -24.9% | 54.0% | -49.9% |
| ROIC | -43.5% | -43.5% | -226.8% | -199.8% | -121.2% | -41.5% | 92.0% | — |
| ROCE | -49.4% | -49.4% | -78.5% | -69.8% | -63.8% | -26.7% | 69.8% | -64.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.04 | 0.18 | 0.10 | 0.19 | 0.22 | 0.21 | — |
| Debt / EBITDA | — | — | — | — | — | — | 0.39 | — |
| Net Debt / Equity | — | -0.03 | -0.16 | -0.88 | -0.29 | -0.64 | -0.11 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | -0.21 | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | 56.15 | 56.15 | -106.11 | -132.83 | -61.06 | -57.22 | 43.88 | -19.97 |
Net cash position: cash ($11M) exceeds total debt ($6M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.46 | 9.46 | 2.98 | 5.45 | 1.47 | 1.90 | 3.11 | 2.01 |
| Quick Ratio | 9.46 | 9.46 | 2.98 | 5.45 | 1.47 | 1.90 | 3.11 | 2.01 |
| Cash Ratio | 9.04 | 9.04 | 2.60 | 5.23 | 1.00 | 1.26 | 1.14 | 1.37 |
| Asset Turnover | — | — | 0.03 | 0.03 | 0.47 | 0.75 | 0.98 | 0.19 |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 15.17 | — | 84.85 | 48.03 | 135.92 | 298.91 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 21.5% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 21.5% | 0.0% | — | — |
| Shares Outstanding | — | $61M | $9M | $6M | $4M | $3M | $3M | $4M |
Imminent liquidity depletion
Based on reported figures, SABS trades at a P/B of 1.54, a multiple that appears to reflect a significant distress discount compared to clinical-stage peers, suggesting the market is pricing in a high probability of failure for the company's proprietary transchromosomic bovine platform.
The negative P/E ratio is a direct consequence of the company's lack of commercial revenue and ongoing clinical-stage losses. Investors should monitor whether the current valuation provides any floor or if the market is effectively assigning zero terminal value to the pipeline until further clinical data for SAB-142 is released.
According to recent financial statements, the company's ROIC has remained consistently negative, with a -8.3% reading in 2026Q1, highlighting the inability of the current business model to generate returns on the capital invested into the specialized bovine herd and clinical development programs.
The persistent negative ROIC trend suggests that the company is currently destroying shareholder value rather than compounding it. This decay in returns is driven by the high fixed-cost nature of the platform, which requires significant capital expenditure without the benefit of offsetting commercial product margins.
As reported in quarterly filings, the current ratio of 11.45 in 2026Q1 appears deceptively strong, yet it masks the reality that the company's cash reserves are rapidly depleting against a high quarterly burn rate, leaving little room for operational error or unexpected clinical delays.
While the current ratio suggests an ability to cover short-term liabilities, the lack of recurring revenue means that liquidity is entirely dependent on external financing. This reliance warrants investigation into the company's ability to secure further capital without causing severe dilution to existing equity holders.
Based on a comparison with industry peers like ADMA Biologics, which maintains a positive net margin of 28.8%, SABS's lack of commercial operations highlights a structural gap that is unlikely to close until the company successfully transitions from a clinical-stage entity to a commercial manufacturer.
Unlike peers that have successfully commercialized plasma-derived or monoclonal therapies, SABS remains in a high-risk development phase. The valuation gap between SABS and its peers appears to be a reflection of this fundamental difference in operational maturity and the associated execution risk.
The P/E ratio is the most commonly misapplied metric for SABS, as it obscures the company's lack of commercial revenue and ignores the significant R&D investment required to maintain the proprietary platform, rendering traditional earnings-based valuation entirely irrelevant for this clinical-stage business model.
Investors should instead focus on cash runway and the probability-weighted net present value of the SAB-142 pipeline. Using P/E to evaluate a pre-revenue biotech firm may lead to erroneous conclusions about the company's financial health and its potential for future value creation.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SABS stock.
SAB Biotherapeutics, Inc.'s current P/E ratio is -4.9x. This places it at the 50th percentile of its historical range.
SAB Biotherapeutics, Inc.'s return on equity (ROE) is 15.0%. The historical average is -25.1%.
Based on historical data, SAB Biotherapeutics, Inc. is trading at a P/E of -4.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.